TrialThe Lancet. Infectious diseases2023

Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.

Jun-Dong Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.